WuXi AppTec highlights how the increasing structural complexity of small molecules, such as targeted protein degraders and covalent inhibitors, is transforming drug research and development. These new molecules require advanced, integrated approaches combining discovery, development, and manufacturing under one partner to improve success rates and accelerate timelines. Early process development and unified quality systems are crucial for handling these complex drugs from discovery through commercial supply. This shift aims to make drug development more predictable and efficient, benefiting biotech and pharmaceutical innovators.
Vaxart, a clinical-stage biotech company, has published a presentation urging shareholders to vote for all six of its director nominees at the upcoming Annual Meeting. The company highlights its progress in developing oral vaccines for COVID-19, noro...
Axsome Therapeutics has initiated the FOCUS-3 Phase 3 clinical trial to evaluate solriamfetol as a treatment for adolescents aged 12 to under 18 with ADHD. This randomized, double-blind, placebo-controlled study will enroll about 468 patients to asse...
At its Annual General Meeting on June 25, 2026, Fury Gold Mines shareholders approved fixing the board size at six directors and elected all nominated directors. PricewaterhouseCoopers LLP was appointed as the company's auditor. Shareholders also ren...
SoundHound AI's Chief Operating Officer has sold 65,000 shares of the company's stock. This insider sale could indicate personal financial decisions or a strategic move related to the company's outlook. Investors often watch such transactions closely...
The global coaxial cable market, valued at $21.58 billion in 2025, is projected to grow to $46.24 billion by 2035, expanding at a CAGR of 7.94%. This growth is fueled by rising broadband demand, high-speed internet infrastructure investments, and inc...
